2Borras-Blasco J, Navrro-Ruiz A, Borras C , et al. Adverse cutaneous reactions in- duced by TNF- a antagonlst therapy[J]. Sout hem Med J, 2()09,102 : 1133-1140.
3Zink A,Braun J,et al. Disability and handicap in rheumatoid arthritis and ankylo- sing spondylitis : results from the German rheurnatological database[J]. J Rheuma- tol.2000,27,613-622.
二级参考文献26
1Calabrese LH. Molecular differences in anticytokine therapies.Clin Exp Rheumatol,2003,21:241-248.
2Feldmann M,Brennan FM,Maini RN. Role of cytokines in rheumatoid arthritis.Annu Rev Immunol,1996,14:397-440.
3Butler DM,Maini RN,Feldmann M,et al.Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures:comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw,1995,6:225-230.
4Braun J,Sieper J.The sacroiliac joint in the spondyloarthropathies.Curr Opin Rheumatol,1996,8:275-297.
5Sandborn WJ,Hanauer SB.Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents,pharmacology,clinical results and safety.Inflamm Bowel Dis,1999,5:119-133.
6Brandt J,Haibel H,Comely D,et al.Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.Arthritis Rheum,2000,43:1346-1352.
7Brandt J,Haibel H,Sieper J,et al.Infliximab treatment of severe ankylosing spondylitis:one-year followup.Arthritis Rheum,2001,44:2936-2937.
8Allali F,Roux C,Kolta S,et al.Infliximab in the treatment of spondyloarthropathy, bone mineral density effect. Arthritis Rheum,2001,44:S89.
9Braun J,Brandt J,Listing J,et al.Treatment of active ankylosings with infliximab:a randomized controlled multicentre trial.Lancet,2002,359:1187-1193.
10Van Den Bosch F,Kruithof E,Baeten D,et al.Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha(infliximab)versus placebo in active spondylarthropathy.Arthritis Rheum,2002,46:755-765.
